A Pilot Study of the Neural Correlates of Treatment Effect on Nicotine Craving
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to gather pilot data to determine feasibility of and guide the development of a larger clinical trial investigating the effects of topiramate as an adjunct to nicotine replacement therapy and behavioral counseling in smoking cessation treatment. It is hypothesized that topiramate will decrease nicotine craving and result in improved outcomes for smoking cessation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Male, between ages of 18-55
Meets DSM-IV criteria for nicotine dependence
Smoke at least 20 cigarettes per day
Motivated to quit smoking
Serious or unstable medical conditions
Current psychiatric disorder requiring medication or treatment
Taking medication that create risk of interaction with study drug
Current participation in another smoking cessation treatment